Medical management of ulcerative colitis
Medical management of IBD varies with respect to disease severity:
Considered in terms of:
- acute attacks
- maintenance of remission of IBD
Related pages
- Maintenance therapy in UC
- Management of acute ulcerative colitis
- Chronic ulcerative colitis
- Leukapharesis for inflammatory bowel disease
- Clinical based scales to assess severity of ulcerative colitis (UC)
- Infliximab in Crohn's disease and ulcerative (UC) colitis
- NICE guidance - Tofacitinib for moderately to severely active ulcerative colitis
- NICE guidance - Vedolizumab for treating moderately to severely active ulcerative colitis
- NICE guidance - Ustekinumab for treating moderately to severely active ulcerative colitis
- Faecal microbiota transplantation (FMT) in ulcerative colitis (UC)
- Filgotinib for treating moderately to severely active ulcerative colitis
- Ozanimod for treating moderately to severely active ulcerative colitis
- Upadacitinib for treating moderately to severely active ulcerative colitis (UC)
- Mirikizumab for treating moderately to severely active ulcerative colitis (UC)
- Exercise and inflammatory bowel disease (IBD)
- Risankizumab for treating moderately to severely active ulcerative colitis
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.